Series A
$35M
5Y CapitalNRL CapitalBioTrack CapitalHongShan (ex Sequoia China) · LeadQiming Venture PartnersMPCi (Matrix Partners China)
Open roles0
Total raised$35M
Team size11-50
Founded · Stage2023 · Series A
We pull jobs from sources most job seekers never check
About the company
What they build and who they serve.
Aureka Biotechnologies is a tech-bio company founded in 2023 with R&D operations in Suzhou and California that develops antibody therapeutics through its proprietary AuraIDE generative-AI platform. The platform pairs foundation models and AI agents with a high-throughput single-cell functional screening system to design differentiated antibodies for cardiometabolic, immune, and central-nervous-system disease targets that are difficult to address with conventional discovery methods. The company has built a BD/NewCo collaboration model with multiple multinational pharmaceutical companies and is preparing its first internally-designed antibody to enter clinical trials.
Why it matters
Signals from funding, traction, and product direction.
- Series A+ extension brings cumulative Series A funding for Aureka Biotechnologies close to USD 100 million within roughly six months of the original Series A.
- Round was led by HongShan (formerly Sequoia Capital China) with new participation from MPCi (Matrix Partners China) and BioTrack Capital, and continued investment from existing shareholders 5Y Capital, Qiming Venture Partners, and NRL Capital.
- One of Aureka's internally-designed antibodies is about to enter clinical trials and two further candidates are in IND-enabling development across multispecific, agonistic, internalizing and pH-switch antibody programs.
- Founder/CEO Zhao Weian states the company has generated tens of millions of US dollars in revenue over the past two years through BD and NewCo collaborations with multiple multinational pharmaceutical companies.
Funding history
Rounds and investors over time, newest first.
In the news
Press, announcements, and coverage about this company.
Investors
5Y CapitalNRL CapitalBioTrack CapitalHongShan (ex Sequoia China)Qiming Venture PartnersMPCi (Matrix Partners China)
Focus areas
B2BGenerative AIBiotechnologyClinical TrialsHealthtech
No open roles on the board yet
We do not have indexed listings for Aureka Biotechnologies right now. Roles may still be open on the company site—we will add them here when they appear in our feed.
Don’t get beat to tomorrow’s openings
New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job posts